Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad based support even from political foes”, the analyst tells investors in a research note. There should be demand for Journavx as an alternative to opioids, even if it takes some time, Truist adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital
- Vertex Pharmaceuticals’ Journavx: Strategic Market Adoption and Growth Outlook
- Vertex Pharmaceuticals price target raised to $459 from $450 at Morgan Stanley
- Vertex Pharmaceuticals: Mixed Financial Performance and Future Prospects Lead to Hold Rating
- Vertex Pharmaceuticals: Hold Rating Due to Mixed Outlook and Generic Competition Risks